Uncategorized

Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24

Merus N.V. announced updated interim clinical data on MCLA-129 from ongoing expansion cohorts in non-small cell lung cancer and in previously treated head and neck squamous cell carcinoma were presented at the European Society for Medical Oncology Asia Congress 2023.

Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24 Read More »

Scroll to Top